217 related articles for article (PubMed ID: 18191104)
21. Contribution of the N-glucuronidation pathway to the overall in vitro metabolic clearance of midazolam in humans.
Klieber S; Hugla S; Ngo R; Arabeyre-Fabre C; Meunier V; Sadoun F; Fedeli O; Rival M; Bourrie M; Guillou F; Maurel P; Fabre G
Drug Metab Dispos; 2008 May; 36(5):851-62. PubMed ID: 18256203
[TBL] [Abstract][Full Text] [Related]
22. Differential induction of midazolam metabolism in the small intestine and liver by oral and intravenous dexamethasone pretreatment in rat.
Eeckhoudt SL; Horsmans Y; Verbeeck RK
Xenobiotica; 2002 Nov; 32(11):975-84. PubMed ID: 12487727
[TBL] [Abstract][Full Text] [Related]
23. Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam.
Granvil CP; Yu AM; Elizondo G; Akiyama TE; Cheung C; Feigenbaum L; Krausz KW; Gonzalez FJ
Drug Metab Dispos; 2003 May; 31(5):548-58. PubMed ID: 12695342
[TBL] [Abstract][Full Text] [Related]
24. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
[TBL] [Abstract][Full Text] [Related]
25. Variability in Expression of CYP3A5 in Human Fetal Liver.
Vyhlidal CA; Pearce RE; Gaedigk R; Calamia JC; Shuster DL; Thummel KE; Leeder JS
Drug Metab Dispos; 2015 Aug; 43(8):1286-93. PubMed ID: 25979262
[TBL] [Abstract][Full Text] [Related]
26. Factors influencing midazolam hydroxylation activity in human liver microsomes.
He P; Court MH; Greenblatt DJ; von Moltke LL
Drug Metab Dispos; 2006 Jul; 34(7):1198-207. PubMed ID: 16638818
[TBL] [Abstract][Full Text] [Related]
27. Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation.
Khan KK; He YQ; Domanski TL; Halpert JR
Mol Pharmacol; 2002 Mar; 61(3):495-506. PubMed ID: 11854429
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of cytochrome P450 2C8-mediated drug metabolism by the flavonoid diosmetin.
Quintieri L; Palatini P; Moro S; Floreani M
Drug Metab Pharmacokinet; 2011; 26(6):559-68. PubMed ID: 21791871
[TBL] [Abstract][Full Text] [Related]
29. Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models.
Vossen M; Sevestre M; Niederalt C; Jang IJ; Willmann S; Edginton AN
Theor Biol Med Model; 2007 Mar; 4():13. PubMed ID: 17386084
[TBL] [Abstract][Full Text] [Related]
30. Effects of bioflavonoids on hepatic P450 activities.
Obermeier MT; White RE; Yang CS
Xenobiotica; 1995 Jun; 25(6):575-84. PubMed ID: 7483658
[TBL] [Abstract][Full Text] [Related]
31. Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs.
Walsky RL; Obach RS; Hyland R; Kang P; Zhou S; West M; Geoghegan KF; Helal CJ; Walker GS; Goosen TC; Zientek MA
Drug Metab Dispos; 2012 Sep; 40(9):1686-97. PubMed ID: 22645092
[TBL] [Abstract][Full Text] [Related]
32. Identification of the active components in Shenmai injection that differentially affect Cyp3a4-mediated 1'-hydroxylation and 4-hydroxylation of midazolam.
Zeng C; He F; Xia C; Zhang H; Xiong Y
Drug Metab Dispos; 2013 Apr; 41(4):785-90. PubMed ID: 23340957
[TBL] [Abstract][Full Text] [Related]
33. In vitro inhibition of midazolam and quinidine metabolism by flavonoids.
Ha HR; Chen J; Leuenberger PM; Freiburghaus AU; Follath F
Eur J Clin Pharmacol; 1995; 48(5):367-71. PubMed ID: 8641324
[TBL] [Abstract][Full Text] [Related]
34. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients.
Thummel KE; Shen DD; Podoll TD; Kunze KL; Trager WF; Hartwell PS; Raisys VA; Marsh CL; McVicar JP; Barr DM
J Pharmacol Exp Ther; 1994 Oct; 271(1):549-56. PubMed ID: 7965755
[TBL] [Abstract][Full Text] [Related]
35. CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin.
Elens L; Nieuweboer A; Clarke SJ; Charles KA; de Graan AJ; Haufroid V; Mathijssen RH; van Schaik RH
Pharmacogenomics; 2013 Jan; 14(2):137-49. PubMed ID: 23327575
[TBL] [Abstract][Full Text] [Related]
36. Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes.
van Waterschoot RA; van Herwaarden AE; Lagas JS; Sparidans RW; Wagenaar E; van der Kruijssen CM; Goldstein JA; Zeldin DC; Beijnen JH; Schinkel AH
Mol Pharmacol; 2008 Mar; 73(3):1029-36. PubMed ID: 18156313
[TBL] [Abstract][Full Text] [Related]
37. Cytochrome P450 3A-dependent metabolism of a potent and selective gamma-aminobutyric acid Aalpha2/3 receptor agonist in vitro: involvement of cytochrome P450 3A5 displaying biphasic kinetics.
Ma B; Polsky-Fisher SL; Vickers S; Cui D; Rodrigues AD
Drug Metab Dispos; 2007 Aug; 35(8):1301-7. PubMed ID: 17460031
[TBL] [Abstract][Full Text] [Related]
38. Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation.
Sugiyama M; Fujita K; Murayama N; Akiyama Y; Yamazaki H; Sasaki Y
Drug Metab Dispos; 2011 May; 39(5):757-62. PubMed ID: 21266595
[TBL] [Abstract][Full Text] [Related]
39. Comparative study of the metabolism of drug substrates by human cytochrome P450 3A4 expressed in bacterial, yeast and human lymphoblastoid cells.
Andrews J; Abd-Ellah MF; Randolph NL; Kenworthy KE; Carlile DJ; Friedberg T; Houston JB
Xenobiotica; 2002 Nov; 32(11):937-47. PubMed ID: 12487724
[TBL] [Abstract][Full Text] [Related]
40. In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies.
Prueksaritanont T; Kuo Y; Tang C; Li C; Qiu Y; Lu B; Strong-Basalyga K; Richards K; Carr B; Lin JH
Drug Metab Dispos; 2006 Sep; 34(9):1546-55. PubMed ID: 16782766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
